RxDoctor Payments Data

Julia Robertson, MD

Family Medicine · Yakima, WANPI 1578572178

Payments from drug & device makers

$2,462in general payments, 2019–2025

Across 125 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$803
  • Sanofi-aventis U.S. LLC$281
  • GSK$276
  • Pfizer$236
  • Johnson & Johnson$170
  • Amgen$135
  • plus $562 from 14 others

What the payments were for

  • Food & beverage$2,44799%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,462 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$17,161
Medicare patients
103
Services billed
234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$26,047
ViberziEluxadoline12$19,321
Xtampza ErOxycodone Myristate12$14,595
EliquisApixaban17$11,664
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$4,872
Breo ElliptaFluticasone/Vilanterol11$4,497
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen76$3,404
Dexlansoprazole DrDexlansoprazole12$2,242
Levothyroxine Sodium121$1,383
Duloxetine Hcl29$918
Methylphenidate ErMethylphenidate Hcl11$891
Hydroxyzine Hcl23$864
Bupropion XlBupropion Hcl29$851
Albuterol Sulfate HfaAlbuterol Sulfate31$813
Venlafaxine Hcl ErVenlafaxine Hcl21$785

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$103$26,04725 claims
AbbVieViberzi$128$19,32112 claims
PfizerEliquis$236$11,66417 claims
GSKBreo Ellipta$276$4,49711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Yakima

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →